NM_012434.5:c.406A>G
Variant summary
Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM2PM5PP3_ModeratePP5_Very_Strong
The NM_012434.5(SLC17A5):c.406A>G(p.Lys136Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000874 in 1,614,010 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K136R) has been classified as Likely pathogenic.
Frequency
Consequence
NM_012434.5 missense
Scores
Clinical Significance
Conservation
Publications
- free sialic acid storage diseaseInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- Salla diseaseInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Genomics England PanelApp, Myriad Women’s Health
- free sialic acid storage disease, infantile formInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
- intermediate severe Salla diseaseInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 14 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_012434.5. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SLC17A5 | NM_012434.5 | MANE Select | c.406A>G | p.Lys136Glu | missense | Exon 3 of 11 | NP_036566.1 | ||
| SLC17A5 | NM_001382633.1 | c.406A>G | p.Lys136Glu | missense | Exon 3 of 12 | NP_001369562.1 | |||
| SLC17A5 | NM_001382631.1 | c.427A>G | p.Lys143Glu | missense | Exon 4 of 12 | NP_001369560.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SLC17A5 | ENST00000355773.6 | TSL:1 MANE Select | c.406A>G | p.Lys136Glu | missense | Exon 3 of 11 | ENSP00000348019.5 | ||
| SLC17A5 | ENST00000481996.1 | TSL:4 | n.172A>G | non_coding_transcript_exon | Exon 2 of 5 |
Frequencies
GnomAD3 genomes AF: 0.0000724 AC: 11AN: 152012Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000318 AC: 8AN: 251472 AF XY: 0.0000368 show subpopulations
GnomAD4 exome AF: 0.0000889 AC: 130AN: 1461880Hom.: 0 Cov.: 31 AF XY: 0.0000990 AC XY: 72AN XY: 727242 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152130Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 4AN XY: 74352 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Salla disease Pathogenic:9
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com.
Variant summary: SLC17A5 c.406A>G (p.Lys136Glu) results in a conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251472 control chromosomes (gnomAD). c.406A>G has been reported in the literature in individuals affected with Salla disease (Morin_2004, Mochel_2009). These data indicate that the variant is likely to be associated with disease. Multiple publications reported experimental evidence evaluating an impact on protein function and this variant affected the SLC17A5 protein function (Miyaji_2011, Morin_2004, Wreden_2005). The following publications have been ascertained in the context of this evaluation (PMID: 21781115, 20101035, 15510212, 15516337). ClinVar contains an entry for this variant (Variation ID: 21493). Based on the evidence outlined above, the variant was classified as pathogenic.
This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 136 of the SLC17A5 protein (p.Lys136Glu). This variant is present in population databases (rs80338795, gnomAD 0.007%). This missense change has been observed in individuals with SLC17A5-related conditions (PMID: 10947946, 16170568, 19557856). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 21493). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SLC17A5 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects SLC17A5 function (PMID: 15510212, 15516337, 21781115). For these reasons, this variant has been classified as Pathogenic.
not provided Pathogenic:4
SLC17A5: PM3:Strong, PS4, PM2, PS3:Supporting
Published functional studies demonstrate approximately 10% residual enzyme activity compared to wild-type, similar to the R39C variant, the common variant associated with Salla disease (PMID: 15516337); Another published functional study found that K136E mutant sialin protein did not transport aspartate and glutamate; however, H+/sialic acid co-transport activity was 50% of the wild-type protein, which was also similar to the results seen for the R39C variant (PMID: 21781115); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 10947946, 19557856, 15510212, 33862140, 16170568, 32371413, 32608236, 36662855, 37713976, 37272184, 21781115, 15516337)
PP1_strong, PP3, PM2_moderate, PM3_very_strong, PS3, PS4_moderate
Sialic acid storage disease, severe infantile type;C1096903:Salla disease Pathogenic:2
[ACMG/AMP: PS3, PM2, PS4_Moderate, PP3, PP5] This alteration is supported by well-established in vitro or in vivo functional studies to have a damaging effect on protein function or splicing [PS3], is absent from or rarely observed in large-scale population databases [PM2], has previously been observed in multiple unrelated patients with the same phenotype [PS4_Moderate], is predicted to be damaging by multiple functional prediction tools [PP3], was reported as a pathogenic/likely pathogenic alteration by a reputable source (ClinVar or other correspondence from a clinical testing laboratory) [PP5].
Sialic acid storage disease, severe infantile type Other:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at